PROQR THERAPEUTICS NV (PRQR) Stock Price & Overview
NASDAQ:PRQR • NL0010872495
Current stock price
The current stock price of PRQR is 1.75 USD. Today PRQR is up by 8.02%. In the past month the price increased by 8%. In the past year, price increased by 37.29%.
PRQR Key Statistics
- Market Cap
- 184.38M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.46
- Dividend Yield
- N/A
PRQR Stock Performance
PRQR Stock Chart
PRQR Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PRQR. When comparing the yearly performance of all stocks, PRQR turns out to be only a medium performer in the overall market: it outperformed 57.85% of all stocks.
PRQR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PRQR. Both the profitability and financial health of PRQR have multiple concerns.
PRQR Earnings
On March 12, 2026 PRQR reported an EPS of -0.08 and a revenue of 4.69M. The company beat EPS expectations (18.82% surprise) and beat revenue expectations (20.7% surprise).
PRQR Forecast & Estimates
15 analysts have analysed PRQR and the average price target is 8.8 USD. This implies a price increase of 402.71% is expected in the next year compared to the current price of 1.75.
For the next year, analysts expect an EPS growth of -37.89% and a revenue growth 26.43% for PRQR
PRQR Groups
Sector & Classification
PRQR Financial Highlights
Over the last trailing twelve months PRQR reported a non-GAAP Earnings per Share(EPS) of -0.46. The EPS decreased by -28.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.41% | ||
| ROE | -85.44% | ||
| Debt/Equity | 0.19 |
PRQR Ownership
PRQR Latest News, Press Relases and Analysis
PRQR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.47 | 384.559B | ||
| AMGN | AMGEN INC | 15.5 | 189.672B | ||
| GILD | GILEAD SCIENCES INC | 15.82 | 173.017B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.14 | 113.435B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.59 | 81.684B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.23 | 43.88B | ||
| INSM | INSMED INC | N/A | 35.247B | ||
| NTRA | NATERA INC | N/A | 28.345B | ||
| BIIB | BIOGEN INC | 11.38 | 26.906B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.5 | 25.99B | ||
| MRNA | MODERNA INC | N/A | 20.063B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.272B | ||
| INCY | INCYTE CORP | 12.34 | 18.731B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PRQR
Company Profile
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company is headquartered in Leiden, Zuid-Holland and currently employs 187 full-time employees. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The firm operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
Company Info
IPO: 2014-09-18
PROQR THERAPEUTICS NV
Zernikedreef 9
Leiden ZUID-HOLLAND 2333 CK NL
CEO: Daniel de Boer
Employees: 187
Phone: 31881667000
PROQR THERAPEUTICS NV / PRQR FAQ
What does PROQR THERAPEUTICS NV do?
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company is headquartered in Leiden, Zuid-Holland and currently employs 187 full-time employees. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The firm operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
Can you provide the latest stock price for PROQR THERAPEUTICS NV?
The current stock price of PRQR is 1.75 USD. The price increased by 8.02% in the last trading session.
What is the dividend status of PROQR THERAPEUTICS NV?
PRQR does not pay a dividend.
What is the ChartMill rating of PROQR THERAPEUTICS NV stock?
PRQR has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is PROQR THERAPEUTICS NV worth?
PROQR THERAPEUTICS NV (PRQR) has a market capitalization of 184.38M USD. This makes PRQR a Micro Cap stock.
What is the next earnings date for PRQR stock?
PROQR THERAPEUTICS NV (PRQR) will report earnings on 2026-05-06.